Nuvalent, Inc.

GSK plc has entered into an agreement to acquire Nuvalent, Inc. for $10.6 billion. The acquisition includes Nuvalent's portfolio of oncology assets, notably two late-stage inhibitors for non-small cell lung cancer (NSCLC): zidesamtinib (ROS1) and neladalkib (ALK). The deal, valued at $124 per share in cash, represents a significant premium and is expected to accelerate GSK's entry into the lung cancer market. The acquisition is projected to be accretive to GSK's financial performance starting in 2027 and is anticipated to close in the third quarter of 2026, subject to regulatory approvals.

Nuvalent, Inc. reported a significant increase in its net loss for the first quarter of 2026, reaching $(109.3) million, up from $(84.6) million in the prior year. This was primarily driven by higher research and development and general and administrative expenses as the clinical-stage biopharmaceutical company continues its development programs. Despite the losses, Nuvalent believes its existing cash, cash equivalents, and marketable securities are sufficient to fund operations for at least the next 12 months.

Nuvalent reported a Q1 2026 net loss of $109.3 million and R&D expenses of $83.6 million. The company announced significant pipeline progress, including the submission of an NDA for neladalkib in TKI pre-treated ALK-positive NSCLC and the ongoing FDA review of zidesamtinib's NDA for TKI pre-treated ROS1-positive NSCLC with a PDUFA date of September 18, 2026. Nuvalent also plans a label expansion submission for zidesamtinib in TKI-naïve ROS1-positive NSCLC in H2 2026 and continues enrollment in its ALKAZAR and HEROEX-1 trials. The company strengthened its leadership team with two key promotions and maintains a strong cash position of $1.3 billion, sufficient to fund operations into 2029.

Nuvalent, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 16, 2026. Stockholders will vote on the election of two Class II directors, an advisory resolution on named executive officer compensation, and the ratification of KPMG LLP as the independent registered public accounting firm for 2026. The board also plans to reduce its size from nine to eight directors following the meeting.

Nuvalent has submitted a New Drug Application (NDA) to the FDA for neladalkib, a treatment for tyrosine kinase inhibitor pre-treated advanced ALK-positive non-small cell lung cancer. This submission marks a significant regulatory milestone for Nuvalent and could lead to a new treatment option for patients with this specific type of lung cancer, potentially impacting the company's future revenue and market position.

Nuvalent has submitted a New Drug Application (NDA) to the FDA for neladalkib, a treatment for tyrosine kinase inhibitor pre-treated advanced ALK-positive non-small cell lung cancer. This submission marks a significant regulatory milestone for Nuvalent and could lead to a new treatment option for patients with this specific type of lung cancer, potentially impacting the company's future revenue and market position.